A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Jan 5

PMID 33396288

Citations 6

Authors

Ryan P Bennett

Courtney L Finch

Elena N Postnikova

Ryan A Stewart

Yingyun Cai

Shuiqing Yu

Janie Liang

Julie Dyall

Jason D Salter

Harold C Smith

Jens H Kuhn

Affiliations

Soon will be listed here.

Abstract

Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody-based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane. Using this assay, we screened nearly 3000 small molecules and identified several molecules with the desired inhibitory properties. In secondary assays, one identified compound, sangivamycin, inhibited not only Ebola viral infectivity but also that of other viruses. This finding indicates that it is possible for this new VP40-based screening method to identify highly potent MCMs against Ebola virus and its relatives.

Citing Articles

N-Substituted Pyrrole-Based Heterocycles as Broad-Spectrum Filoviral Entry Inhibitors.

Durante D, Bott R, Cooper L, Owen C, Morsheimer K, Patten J J Med Chem. 2024; 67(16):13737-13764.

PMID: 39169825 PMC: 11812679. DOI: 10.1021/acs.jmedchem.4c00527.

Development of a Crystallographic Screening to Identify Sudan Virus VP40 Ligands.

Werner A, Krapoth N, Norris M, Heine A, Klebe G, Saphire E ACS Omega. 2024; 9(30):33193-33203.

PMID: 39100314 PMC: 11292656. DOI: 10.1021/acsomega.4c04829.

Evaluation of fendiline treatment in VP40 system with nucleation-elongation process: a computational model of Ebola virus matrix protein assembly.

Liu X, Husby M, Stahelin R, Pienaar E Microbiol Spectr. 2024; 12(4):e0309823.

PMID: 38407984 PMC: 10986538. DOI: 10.1128/spectrum.03098-23.

Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.

Broni E, Ashley C, Adams J, Manu H, Aikins E, Okom M Int J Mol Sci. 2023; 24(7).

PMID: 37047270 PMC: 10094735. DOI: 10.3390/ijms24076298.

Generation of Reporter-Expressing New World Arenaviruses: A Systematic Comparison.

Feneant L, Leske A, Gunther K, Groseth A Viruses. 2022; 14(7).

PMID: 35891543 PMC: 9317149. DOI: 10.3390/v14071563.

References

Timmins J, Scianimanico S, Schoehn G, Weissenhorn W . Vesicular release of ebola virus matrix protein VP40. Virology. 2001; 283(1):1-6. DOI: 10.1006/viro.2001.0860. View

Gomis-Ruth F, Dessen A, Timmins J, Bracher A, Kolesnikowa L, Becker S . The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure. 2003; 11(4):423-33. PMC: 7126486. DOI: 10.1016/s0969-2126(03)00050-9. View

Kugelman J, Kugelman-Tonos J, Ladner J, Pettit J, Keeton C, Nagle E . Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell Rep. 2015; 12(12):2111-20. DOI: 10.1016/j.celrep.2015.08.038. View

Hoenen T, Jung S, Herwig A, Groseth A, Becker S . Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology. 2010; 403(1):56-66. DOI: 10.1016/j.virol.2010.04.002. View

Osada H, Sonoda T, Tsunoda K, Isono K . A new biological role of sangivamycin; inhibition of protein kinases. J Antibiot (Tokyo). 1989; 42(1):102-6. DOI: 10.7164/antibiotics.42.102. View

Bornholdt Z, Noda T, Abelson D, Halfmann P, Wood M, Kawaoka Y . Structural rearrangement of ebola virus VP40 begets multiple functions in the virus life cycle. Cell. 2013; 154(4):763-74. PMC: 4138722. DOI: 10.1016/j.cell.2013.07.015. View

Bastea L, Hollant L, Doppler H, Reid E, Storz P . Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death. Sci Rep. 2019; 9(1):16588. PMC: 6851150. DOI: 10.1038/s41598-019-53223-0. View

Zhao Y, Ren J, Harlos K, Jones D, Zeltina A, Bowden T . Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature. 2016; 535(7610):169-172. PMC: 4947387. DOI: 10.1038/nature18615. View

Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, Muhlberger E . The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology. 2013; 441(2):135-45. PMC: 3773471. DOI: 10.1016/j.virol.2013.03.013. View

10.

Silva L, VanZile M, Bavari S, Aman J, Schriemer D . Assembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tails. PLoS One. 2012; 7(7):e39978. PMC: 3390324. DOI: 10.1371/journal.pone.0039978. View

11.

De Clercq E, Bernaerts R, Bergstrom D, Robins M, Montgomery J, Holy A . Antirhinovirus activity of purine nucleoside analogs. Antimicrob Agents Chemother. 1986; 29(3):482-7. PMC: 180418. DOI: 10.1128/AAC.29.3.482. View

12.

Bai C, Mu J, Kargbo D, Song Y, Niu W, Nie W . Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis. 2016; 63(10):1288-1294. DOI: 10.1093/cid/ciw571. View

13.

Garcia M, Cooper A, Shi W, Bornmann W, Carrion R, Kalman D . Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med. 2012; 4(123):123ra24. PMC: 4794994. DOI: 10.1126/scitranslmed.3003500. View

14.

Adu-Gyamfi E, Soni S, Xue Y, Digman M, Gratton E, Stahelin R . The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J Biol Chem. 2013; 288(8):5779-89. PMC: 3581432. DOI: 10.1074/jbc.M112.443960. View

15.

Schindell B, Webb A, Kindrachuk J . Persistence and Sexual Transmission of Filoviruses. Viruses. 2018; 10(12). PMC: 6316729. DOI: 10.3390/v10120683. View

16.

Hobbs S, Jitrapakdee S, Wallace J . Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun. 1998; 252(2):368-72. DOI: 10.1006/bbrc.1998.9646. View

17.

Bennett R, Stewart R, Hogan P, Ptak R, Mankowski M, Hartman T . An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation. Antiviral Res. 2016; 136:51-59. PMC: 5125868. DOI: 10.1016/j.antiviral.2016.11.001. View

18.

Huang R, Pei L, Liu Q, Chen S, Dou H, Shu G . Isobologram Analysis: A Comprehensive Review of Methodology and Current Research. Front Pharmacol. 2019; 10:1222. PMC: 6830115. DOI: 10.3389/fphar.2019.01222. View

19.

Hoenen T, Groseth A, Kok-Mercado F, Kuhn J, Wahl-Jensen V . Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res. 2011; 91(2):195-208. PMC: 3586226. DOI: 10.1016/j.antiviral.2011.06.003. View

20.

Radzimanowski J, Effantin G, Weissenhorn W . Conformational plasticity of the Ebola virus matrix protein. Protein Sci. 2014; 23(11):1519-27. PMC: 4241103. DOI: 10.1002/pro.2541. View